stockrowPulmonx Corporation (LUNG) vs MaxCyte, Inc. (MXCT)
- Pulmonx Corporation LUNG 2.60 +1.56%
- MaxCyte, Inc. MXCT 1.30 −0.76%
Pulmonx Corporation and MaxCyte, Inc. are both Medical Devices companies. MaxCyte, Inc. is the larger, with a market value of $135.2M against $111.5M — 1.2× the size. Pulmonx Corporation grew revenue faster over the last twelve months: −3.15% against −13.2%. Pulmonx Corporation has the higher net margin (−47.9% vs −114.8%) and the lower return on invested capital (−129.9% vs −49.2%). Across the 18 metrics below, Pulmonx Corporation leads on 9 and MaxCyte, Inc. on 9.
Valuation
Profitability
| Metric | LUNG | MXCT | Medical Devices median |
|---|---|---|---|
| Gross margin | 77.42% | 79.23% | 57.76% |
| Operating margin | (44.39%) | (134.59%) | (15.07%) |
| Net margin | (47.93%) | (114.77%) | (14.45%) |
| Free cash flow margin | (28.85%) | (76.14%) | (3.88%) |
| Return on equity | (90.31%) | (20.39%) | (10.35%) |
| Return on assets | (34.25%) | (17.62%) | (17.26%) |
| Return on invested capital | (129.86%) | (49.23%) | (5.27%) |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack